NCT05865041

Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants

A Parallel Group Treatment, Phase 2a, Double-blind, Two-arm Study to Investigate the Efficacy and Safety of Farudodstat Tablets Compared With Its Placebo in Male or Female Alopecia Areata Participants Aged 18 Years and Older With 30% or Greater Scalp Hair Loss

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: ASLAN Pharmaceuticals · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to measure the efficacy of farudodstat compared to placebo at Week 12 from the treatment start, in adult participants with Alopecia Areata (AA) with 30% or greater scalp hair loss.

Conditions

• Alopecia Areata

Interventions

Type	Name	Description
DRUG	Farudodstat	Farudodstat tablets administered orally
DRUG	Placebo	Placebo tablets administered orally

Timeline

• Start date: 2023-04-14
• Primary completion: 2024-09-12
• Completion: 2024-10-31
• First posted: 2023-05-18
• Last updated: 2023-12-18

Locations

19 sites across 1 country: United States

Regulatory

• FDA-regulated drug study